Antibiotic Resistance

Scientific

The mechanism — Darwinian evolution at microbial scale:

1. A pathogen population is exposed to an antibiotic.
2. Most bacteria in the population are killed.
3. The few that survive — through pre-existing or new mutations — reproduce, sometimes very rapidly. The next generation is, on average, more resistant.
4. Resistance genes spread vertically (parent-to-offspring) and horizontally (between bacteria via plasmids, transposons, transduction).
5. Repeated antibiotic exposure across populations and species selects for ever-broader resistance.

Major drivers:

• Sub-therapeutic agricultural use — antibiotics fed to healthy animals at low doses to promote growth and prevent disease in confinement systems. Roughly 70% of medically-important antibiotics by weight in the U.S. are used in animal agriculture, not human medicine.
• Prescription overuse in human medicine — antibiotics prescribed for viral infections (against which they have no effect), incomplete courses that leave resistant survivors, broad-spectrum use when narrow-spectrum would do.
• Hospital infection-control failures — concentrated drug-resistant pathogens in hospital environments.
• Global supply-chain spread — international travel and food trade move resistant pathogens worldwide.

Major resistant pathogens of public-health concern:

• Methicillin-resistant Staphylococcus aureus (MRSA) — including livestock-associated MRSA strains traced to swine confinement operations.
• Clostridium difficile (C. diff) — hospital-acquired infection often triggered by antibiotic disruption of [[gut-microbiome|gut microbiome]].
• Drug-resistant Salmonella, Campylobacter, E. coli — many traced to agricultural use.
• Multi-drug resistant Mycobacterium tuberculosis (MDR-TB, XDR-TB) — global TB control under pressure.
• Carbapenem-resistant Enterobacteriaceae (CRE) — last-resort-antibiotic resistance.
• Drug-resistant Neisseria gonorrhoeae — gonorrhea increasingly difficult to treat.

Practical

What works (where adopted):

• Reducing agricultural antibiotic use — Denmark, Sweden, Netherlands, and other European nations have substantially reduced agricultural antibiotic use through coordinated policy. The U.S. has begun (2017 FDA rule restricted growth-promotion uses) but remains far behind.
• Prescription stewardship — clinical guidelines reducing inappropriate antibiotic prescription.
• Infection prevention — sanitation, vaccination, hand hygiene reducing infection demand for antibiotics.
• New antibiotic development — pharmaceutical investment is inadequate; the economics of new-antibiotic development are unfavorable to industry without policy intervention.
• Bacteriophage therapy — using viruses that infect bacteria as alternative therapy; emerging area of clinical use.
• Probiotic and microbiome-restoration approaches — particularly for C. diff and post-antibiotic gut dysbiosis.

Cultural

The framing of AMR as “one of the top public health threats” by WHO, CDC, and other bodies has not yet produced policy response proportional to the threat. The structural problem is collective-action: each individual prescriber, patient, farmer, and clinician faces incentives that push toward antibiotic use, while the resistance cost is borne by everyone collectively.

The One Health framework (linking human medicine, veterinary medicine, and ecology) is the conceptual answer; coordinated policy across these domains is the practical answer; political will is the missing input.

Lenses still to grow

• The Danish agricultural-antibiotic reduction case study (1990s onward)
• The 2017 U.S. FDA Veterinary Feed Directive and what it did and didn’t change
• Bacteriophage therapy as emerging field
• The pharmaceutical economics of antibiotic development
• Indigenous and traditional medicine antimicrobial substances and what we can learn

See also

Auto-generated from this entry’s typed relations: frontmatter, grouped by relation type so the editorial signal isn’t flattened.

• Enables: [[factory-farming]]
• Member of: [[threat]]
• Opposes: [[animal-welfare-approved]]
• Threatens: [[modern-medicine]]
• Enabled by: [[factory-farming]]

Sources

• World Health Organization, Global Action Plan on Antimicrobial Resistance
• O’Neill Review on Antimicrobial Resistance (2014–2016, UK government commission)
• Murray et al., “Global burden of bacterial antimicrobial resistance,” The Lancet (2022)
• Pew Charitable Trusts, Antibiotic Resistance Project publications
• David Wallinga et al., research on agricultural-antibiotic-AMR linkage

Rooted in life.